Glutathione Conjugates of Hydralazine Formed in Theperoxidase/Hydrogen Peroxide/Glutathione System

  • Larry G. McGirr
  • Peter J. O’Brien
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 283)


The antihypertensive drug hydralazine is associated withthe induction of symptoms similar to systemic lupuserythematosus (Perry, 1973); it is also associated withlung tumors in mice (Toth, 1978), is mutagenic inseveral short term bacterial and mammalian cell assays (Williams et. al., 1980) and results in the irreversible inactivation of several amine oxidases (Lyles et. al., 1983, Numata et. al., 1981). Mechanisms responsible forthese conditions are unknown.


Amine Oxidase Iodoacetic Acid Glutathione Conjugate Standard Reaction Mixture Thiyl Radical 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Kanazawa, H., Hara, T., Tsutsumino, K., Shibata, Y., Tamura, Z., and Senga, K. (1986). New degradation products in an aqueous solution of hydralazine hydrochloride. Chem. Pharm. Bull. 34, 1840–1842.CrossRefPubMedGoogle Scholar
  2. LaCagnin, L.B., Colby, H. D., and O’Donnell, J.P. (1986). The oxidative metabolism of hydralazine by rat liver microsomes. Drug Metab. Dispos. 14, 549–554.PubMedGoogle Scholar
  3. Lyles, G.A., Garcia-Rodriguez, J., and Callingham, B.A. (1983). Inhibitory actions of hydralazine upon monoamine oxidizing enzymes in the rat. Biochem. Pharmacol. 32, 2515–2521.Google Scholar
  4. Numata, Y., Takei, T., and Hayakawa, T. (1981). Hydralazine as an inhibitor of lysyl oxidase activity. Biochem. Pharmacol. 30, 3125–3126.CrossRefPubMedGoogle Scholar
  5. O’Brien, P.J. (1988). Radical formation during the peroxidase catalyzed metabolism of carcinogens and xenobiotics: the reactivity of these radicals with GSH, DNA and unsaturated lipid. Free Rad. Biol. Med. 4, 169–183.Google Scholar
  6. Perry, Jr., H.M. (1953). A method of quantitatingl-hydralazinophthalazine in body fluids. J. Lab. Clin. Med. 41, 566–572.PubMedGoogle Scholar
  7. Perry, H. M. Jr. (1973). Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am. J. Med. 54, 58–72.CrossRefPubMedGoogle Scholar
  8. Reed, D.J., Babson, J.R., Beatty, P.W., Brodie, A.E.,Ellis, W.W., and Potter, D.W. (1980). High performance liquid chromatographic analysis of nanomole levels of glutathione disulfide and related thiols. Anal. Biochem. 106, 55–62.Google Scholar
  9. Sinha, B.K. (1983). Enzymatic activation of hydrazinederivatives. A spin trapping study. J. Biol. Chem. 258, 786–801.Google Scholar
  10. Streeter, A.J., and Timbre’’, J.A. (1985). Enzyme mediated covalent binding of hydralazine to rat liver microsomes. Drug Metab. Dispos. 13, 255–259.Google Scholar
  11. Toth, B. (1978). Tumorigenic effect of 1-hydrazinophthalazine hydrochloride in mice. J. Natl.Cancer Inst. 61, 1363–1365.Google Scholar
  12. Williams, G.M., Mazue, G., McQueen, C.A., and Shimada, T. (1980). Genotoxicity of the antihypertensive drugs hydralazine and dihydralazine. Science 210, 329–330.CrossRefPubMedGoogle Scholar
  13. Zak, S.B., Gilleran, T.G., Kavliner, J., and Lukas, G. (1974). Identification of two new metabolites of HP from human urine. J. Med. Chem. 17, 381–382.CrossRefPubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Larry G. McGirr
    • 1
  • Peter J. O’Brien
    • 1
  1. 1.Faculty of PharmacyUniversity of TorontoTorontoCanada

Personalised recommendations